Biotech Values

[DewDiligence]

Changes likely coming to drug-approval process in UK:

http://www.reuters.com/article/us-britain-eu-corporates-pharmaceuticals-idUSKCN0ZA26J?utm_campaign=trueAnthem:+Trending+Content&utm_content=576d231904d301109351ca59

Industry executives fear…Britain may have to develop its own domestic regulatory system [for drugs]… Although Britain could continue to take part in the EMA system if it remains in the European Economic Area, like Norway, many of those supporting its exit from the EU oppose that option.

As a result, British patients could move to the back of the queue for new medicines as companies prioritize the larger EU market, and some medicines could be left in regulatory limbo.

If the UK does not remain part of the EMA zone, the double whammy of a separate regulatory agency and the reimbursement wall embodied by NICE will probably cause multinational drugmakers to place even less emphasis on UK commercialization than they do now.